Actively Recruiting
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
Led by NYU Langone Health · Updated on 2026-03-11
302
Participants Needed
2
Research Sites
133 weeks
Total Duration
On this page
Sponsors
N
NYU Langone Health
Lead Sponsor
N
National Institutes of Health (NIH)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The purpose of this an open-label, randomized controlled trial study is to compare the effectiveness of electronic cigarettes (e-cigarettes/e-cigs) versus telehealth motivational counseling with combination nicotine replacement therapy (NRT) + telehealth counseling on combustible cigarettes smoking reduction among persons with opioid use disorder (OUD) in methadone and buprenorphine treatment programs (opioid use disorder treatment programs (OUDTP)). OUDTP patients are a population with exceptionally high combustible cigarettes smoking burden and yet limited success in achieving meaningful clinical outcomes in tobacco treatment. If effective, electronic cigarettes would provide an additional tool for tobacco harm reduction among this difficult-to-treat vulnerable population.
CONDITIONS
Official Title
E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Currently smokes 5 or more combustible cigarettes per day
- Age 21 years or older
- Diagnosed with Opioid Use Disorder
- In methadone or buprenorphine treatment for 12 weeks or more
- Stable methadone or buprenorphine dose for at least two weeks
- Interested in reducing combustible cigarette smoking
- Owns or has regular access to a mobile phone
- Able to provide an additional contact for follow-up
You will not qualify if you...
- Does not speak English or Spanish
- Pregnant or breastfeeding
- Unable to provide consent
- Used tobacco products other than combustible cigarettes in the past 2 weeks
- Currently trying to quit combustible cigarette smoking
- Has severe chronic obstructive pulmonary disease or asthma with recent hospitalization or intubation
- Has current major depressive or manic episode, psychotic disorder, recent suicide attempt or hospitalization, or current suicidal ideation with plan or intent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
NYU Langone Health
New York, New York, United States, 10016
Actively Recruiting
2
Albert Einstein College of Medicine
The Bronx, New York, United States, 10461
Not Yet Recruiting
Research Team
O
Omar El-Shahawy, MD, MPH, PhD
CONTACT
M
Mohsen Abbasi, MD, MPH
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here